UM researchers have developed a deep learning model to predict compound protein interactions. GraphBAN is an inductive ...

Explore how large language models enhance knowledge graphs in drug discovery and improve data management and reasoning.

Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter "Elix"), an AI drug discovery company with the mission of "Rethinking Drug Discovery", today announced that it has entered into a drug discovery ...

Despite issues with data quality and privacy, the use of AI in drug discovery has enormous potential to revolutionize the pharmaceutical sector by providing quicker, more accurate, and more ...

Strategic Partnership Aims to Create a Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with an AI Drug Discovery Platform TOKYO, April 15, 2025--(BUSINESS ...

PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced ...

Elix Inc. has entered into a drug discovery collaboration with Prism Biolab Co. Ltd. to accelerate AI-driven drug discovery for challenging protein-protein interaction targets. The partnership will ...

Drug discovery firm Exscientia has claimed a world first after announcing that the first precision engineered drug generated by artificial intelligence (AI) is entering clinical trials.

announced that it has entered into a drug discovery collaboration with Elix, Inc., an AI drug discovery company, effective April 1, 2025. This partnership will accelerate research on these challenging ...